Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Drug Profile

Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Alternative Names: VP35 siRNA - Alnylam

Latest Information Update: 22 Oct 2013

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Viral haemorrhagic fevers

Most Recent Events

  • 22 Oct 2013 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 31 Dec 2011 No development reported - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 07 Aug 2008 Alnylam is awarded continued funding of $US7.5 million from the US NIAID to support development of an RNAi therapeutic against viral haemorrhagic fevers (including Ebola)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top